Table 3.
Summary of Next-Line Therapy in the Overall Population and by Region
Category | Overall Population |
Central/Eastern Europe |
North America/Western Europe |
Rest of World |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tivozanib (n = 260) |
Sorafenib (n = 257) |
Tivozanib (n = 229) |
Sorafenib (n = 228) |
Tivozanib (n = 22) |
Sorafenib (n = 18) |
Tivozanib (n = 9) |
Sorafenib (n = 11) |
|||||||||
No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % | |
Patients who discontinued assigned therapy* | 190 | 73† | 226 | 88 | 165 | 72 | 198 | 87 | 16 | 73† | 17 | 94 | 9 | 100 | 11 | 100 |
Patients with next-line therapy | 68 | 26 | 168 | 65 | 52 | 23 | 145 | 64 | 13 | 59 | 14 | 78 | 3 | 33 | 9 | 82 |
Patients with next-line targeted therapy | 34 | 13 | 162 | 63 | 26 | 11 | 139 | 61 | 7 | 32 | 14 | 78 | 1 | 11 | 9 | 82 |
VEGFR inhibitor | 18 | 7 | 158 | 61 | 13 | 6 | 138 | 61 | 5 | 23 | 11 | 61 | 0 | 9 | 82 | |
Tivozanib | 0 | 156 | 61 | 0 | 138 | 61 | 0 | 10 | 56 | 0 | 8 | 73 | ||||
mTOR inhibitor | 16 | 6 | 4 | 2 | 13 | 6 | 1 | < 1 | 2 | 9 | 3 | 17 | 1 | 11 | 0 | |
Cytokines | 14 | 5 | 3 | 1 | 14 | 6 | 3 | 1 | 0 | 0 | 0 | 0 | ||||
Radiotherapy | 10 | 4 | 2 | 1 | 4 | 2 | 2 | 1 | 5 | 23 | 0 | 1 | 11 | 0 | ||
Other | 10 | 4 | 1 | < 1 | 8 | 3 | 1 | < 1 | 1 | 5 | 0 | 1 | 11 | 0 |
Abbreviations: mTOR, mammalian target of rapamycin; VEGFR, vascular endothelial growth factor receptor.
On or before August 27, 2012.
One patient erroneously appears as “discontinued” but was ongoing as of August 27, 2012.